EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces that third quarter sales of the company’s prescription daily lid and lash hygiene product Avenova™ are expected to reach more than $1 million. This will be an approximate 30% increase over the second quarter of 2015, with growth driven by record highs for pharmacy-filled prescriptions and products sold directly by eye care specialists.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
